|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 105.24 USD | -0.67% |
|
-0.64% | +6.55% |
| Jan. 15 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
| Jan. 13 | TD Cowen Adjusts Price Target on Incyte to $128 From $101, Maintains Buy Rating | MT |
Business description: Incyte Corporation
- product sales (85.3%);
- royalties (13.7%);
- income from research and cooperation agreements (1%).
Number of employees: 2,617
Sales by Activity: Incyte Corporation
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
Oncology and Dermatology Pharmaceutical Products | 2.67B | 2.99B | 3.39B | 3.7B | 4.24B |
Geographical breakdown of sales: Incyte Corporation
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
United States | 2.6B | 2.9B | 3.2B | 3.5B | 4B |
Europe | 105M | 124M | 147M | - | 260M |
Other Countries | - | - | - | - | 6.2M |
Europe and Japan | - | - | - | 179M | - |
Executive Committee: Incyte Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
William Meury
CEO | Chief Executive Officer | 58 | 2025-06-25 |
Thomas Tray
DFI | Director of Finance/CFO | 49 | 2025-09-15 |
Pablo Cagnoni
PSD | President | 62 | 2023-06-04 |
| Chief Tech/Sci/R&D Officer | 62 | 2015-12-31 | |
Steven Stein
CTO | Chief Tech/Sci/R&D Officer | 59 | 2015-03-01 |
Composition of the Board of Directors: Incyte Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Julian Baker
CHM | Chairman | 59 | 2025-06-25 |
| Director/Board Member | 72 | 2015-01-19 | |
Paul Clancy
BRD | Director/Board Member | 64 | 2015-01-19 |
Jacqualyn Fouse
BRD | Director/Board Member | 64 | 2017-11-13 |
Edmund Harrigan
BRD | Director/Board Member | 73 | 2019-12-15 |
Katherine High
BRD | Director/Board Member | 74 | 2020-03-24 |
Otis Brawley
BRD | Director/Board Member | 66 | 2021-09-26 |
| Director/Board Member | 59 | 2022-09-30 | |
William Meury
BRD | Director/Board Member | 58 | 2025-06-25 |
Holdings: Incyte Corporation
| Name | Equities | % | Valuation |
|---|---|---|---|
MERUS N.V. 1.33% | 1,008,076 | 1.33% | 97 M $ |
| 4,372,124 | 9.99% | 13 M $ |
Company details: Incyte Corporation
Biopharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.67% | -0.64% | +45.24% | +30.20% | 20.66B | |
| -1.62% | -7.38% | +5.47% | +2.74% | 76.12B | |
| +1.97% | +96.50% | +96.50% | +96.50% | 61.96B | |
| -0.04% | +2.77% | +36.36% | +225.51% | 57.24B | |
| +0.14% | +0.71% | -36.31% | -38.82% | 56.7B | |
| -0.44% | -9.37% | +19.55% | -41.48% | 24.73B | |
| +0.56% | +0.28% | +198.50% | +112.71% | 19.8B | |
| +0.75% | -1.67% | +55.02% | +1,234.75% | 17.14B | |
| -3.01% | +16.24% | +13.20% | -79.50% | 15.38B | |
| -2.11% | +3.31% | +117.89% | +771.54% | 14.7B | |
| Average | -0.44% | +0.21% | +55.14% | +231.42% | 36.44B | |
| Weighted average by Cap. | -0.20% | -0.47% | +40.19% | +137.22% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- INCY Stock
- Company Incyte Corporation
Select your edition
All financial news and data tailored to specific country editions
